I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on OCHORUGE 122, 2005

fW

Jacquela P. Bolin

Attorney Docket No. CHM-013M2

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

KENNETH D. R. SETCHELL et al. :

Confirmation No.: 1706

Serial No.: 10/625,989

Group Art Unit: 1614

Filed: 07/24/2003

COMPOSITIONS AND PRODUCTS CONTAINING R-EQUOL, AND METHODS

FOR THEIR MAKING

## <u>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</u> <u>PURSUANT TO 37 CFR 1.56, 1.97 and 1.98</u>

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR §§1.56, 1.97 and 1.98, Applicant request the Examiner to make of record the documents listed on the attached PTO/SB/08 form in connection with examination of the above-identified patent application. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b). In accordance with 37 C.F.R. §1.98(a)(2), Applicants are submitting copies of foreign patent documents and non-patent literature.

Applicants also respectfully request the Examiner to consider and make of record the copending applications listed on the attached page.

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due.

This submission does not represent that a search has been made or that no closer art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicant determines that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Respectfully submitted,

For: Kenneth D. R. SETCHELL et al.

Rv

Daniel F. Nesbitt Attorney for Applicant Registration No. 33,746

(513) 229-0383

Customer Number 38155

October 45, 2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/625,989

Filing Date 07/24/2003

First Named Inventor Kenneth D. R. SETCHELL et al.

Art Unit 1614

Examiner Name

Attorney Docket Number CHM-013M2

(use as many she		
Sheet	of	

U.S. PATENT DOCUMENTS							
Examiner Cite No.1	Cito		Document Number	Dublication Dut		Pages, Columns, Lines, Where	
	No.1	N	lumber - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
		US	4,390,559	06/28/1983	Zilliken		
		US	5,141,746	08/25/1992	Fleury et al.		
		US	5,352,384	10/04/1994	Shen		
		US	5,424,331	06/13/1995	Shlyankevich		
		US	5,523,087	06/04/1996	Shlyankevich		
		US	6,565,864 B2	05/20/2003	Pillai et al.		
		US	6,628,543	10/28/2003	Kang et al.		
		US	2002/0019377 A1	02/14/2002	Jenkins et al.		
·		US	2002/0160064	10/31/2002	Zulli et al.		
		US	2003/0027772 A1	02/06/2003	Breton	<del> </del>	

2

			FOREIG	N PATENT	DOCUMENTS		
Examiner	Cite	F	oreign Patent Document			Pages, Columns, Lines, Where	П
Initials*	No.1		de3-Number4-Kind Code5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	T€
		Japan	H02-124883	05/14/1990	Kitasato Institute	Partial English Translation	
		WO	93/23069	11/25/1993	Kelly, Graham, Edmund		Г
		wo	94/23716	10/27/1994	Tufts University School of Medicine		
		WO	96/10341	04/11/1996	Van Haaster, Joseph, Nicolas		_
		WO	97/06273	02/20/1997	Fermalogic, Inc.		
		WO	98/48790	11/05/1998	Anticancer, Inc.		Г
		WO	02/087517	11/07/2002	Beiersdorf AG	Abstract	
		WO	02/089757	11/14/2002	Beiersdorf AG	Abstract	lacksquare
		WO	04/022023	03/18/2004	Novogen Research		
		WO	04/026274	04/01/2004	Novogen Research PTY Ltd.		Г
		wo	04/039327 A2	05/13/2004	Colorado State University Research Foundation, Brigham Young University; Children's Hospital Medical Center		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	-
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) volume-issue number(s), publisher, city and/or country where published.	Т²
		LUND, TD et al., Equol is a Novel Anti-Androgen that Inhibits Prostate Growth and Hormone Feedback, Biol. Reprod., 2004 Apr; 70(4) 1188-95, E-Pub. 2003 Dec. 17	
		ATKINSON, C. et al, In Vitro Incubation of Human Feces with Daidzein and Antibiotics Suggests Interindividual Differences in the Bacteria Responsible for Equal Production, Amer. Society for Nutritional Sciences, 134:596-599, March 2004	
		SETCHELL, Kenneth, D.R., et al. Phytoestrogens: The Biochemistry, Physiology, and Implications for Human Health of Soy Isoflavones, Am J. Clin Nutri 1998, Pgs. 1333S-1346S	

## INFOR **STATE**

Sheet

MATION DISCLOSURE		Application Number	10/625,989	
MENT BY APPLICANT			Filing Date	07/24/2003
(use as many sheets as necessary)		First Named Inventor	Kenneth D. R. SETCHELL et al.	
		Art Unit	1614	
		Examiner Name	-	
2	of	2	Attorney Docket Number	CHM-013M2

Complete if Known

ALDERCREUTZ, H. et al, Determination of Urinary Lignans And Phytoestrogen Metabolites, Potential Antiestrogen and Anticarcinogens in Urine of Women on Various Habitual Diets, J. Steroid Biochem, Vol. 25, pp 791-797 (1996)	Abstract
THOMPSON, M.A. et al., Characterization of the Estrogenic Properties of A Nonsteroidal Estrogen, Equol, Extracted from Urine of Pregnant Macaques Biol Reprod, Nov 1984; 31: 705 - 713.	
HEDLUND, T.E. et al., Soy Isoflavonoid Equol Modulates the Growth of Benign and Malignant Prostatic Epithelial Cells in Vitro, The Prostate 54:68-78 (2003) accepted May 14, 2002	
DUNCAN, A. M. et al., Premenopausal Equol Excretors Show Plasma Hormone Profiles Associated with Lowered Risk of Breast Cancer, Cancer Epidemiol, Biomarkers Prev Vol. 9: 581-586. June, 2000.	
HWANG, J. et al., The Phytoestrogen Equol Increases Nitric Oxide Availability by Inhibiting Superoxide Production: An Antioxidant Mechanism for Cell-Mediated LDL Modification, Free Radical Biology & Medicine, Vol. 34, No. 10, pp. 1271-1282, (2003)	
MUTHYALA, R. S., Equol, a Natural Estrogenic Metabolite from Soy Isofavones: Convenient Preparation and Resolution of R- and S- Equols and Their Differing Binding and Biological Activity Through Estrogen Receptors Alpha and Beta, Bioorganic & Medicinal Chemistry 12 pp 1559-1567 (2004), accepted November 19, 2003	
SATHYAMOORTHY, N. et al., Differential Effects of Dietary Phyto-oestrogens Daidzein and Equol on Human Breast Cancer MCF-7 Cells, European Journal of Cancer, Volume 33, Issue 14, December 1997, Pages 2384-2389	Abstract
OGAWARA, H., A specific Inhibitor for Tyronsine Protein Kinase from Pseudomonas, The Journal of Antibiotics, Vol. 39(4), Apr. 1936, 606-608	

Examiner	 Date	
Signature	Considered	

	COPENDING U.S. PATENT APPLICATIONS						
Examiner Initials	Applicant(s)	Serial No.	Filing Date	Atty. Docket No.			
	Setchell, et al.	10/625,934	07/24/2003	CHM-013M1			
	Lephart, et al	10/533,045	04/28/2005	CSU-001M			
	Lephart, et al	11/059,951	02/17/2005	CSU-002M			